- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02041767
Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration (ERTAPRO)
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Ertapenem is an antibiotic belonging to carbapenems family and used in infections with Gram-negative bacilli with extended spectrum beta lactamase (ESBL). Its efficacy has been demonstrated in abdominal, soft tissue, pulmonary, skin and gynaecological infections. Recently it has been compared to ceftriaxone in urinary infections demonstrating his efficacy and tolerance.
The purpose of this study is to assess its benefit in probabilistic strategy by demonstrating its prostatic diffusion in significant concentration when administrated in a pre-operative single injection.
Patients were divided in two groups receiving a single injection of 1g of ertapenem 1h or 12h before endoscopic surgery of prostate hyperplasia.
Concentration of ertapenem was measuring on blood sample and on chips resection of prostate during endoscopic surgery.
To demonstrate the prostatic diffusion in significant amount of ertapenem, the prostatic concentration of ertapenem had to be higher than the minimal inhibitory concentration (MIC) for 40% of the time of injection interval.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Paris, Frankrig, 75908 Cedex 15
- HEGP Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Acceptance and understanding of the consent form (signed)
- 18-80 years old patients
- BPH needing endoscopic resection according to French Urology Association recommendations
- Procedure and follow up made in investigator center
- normal digital rectal examination
- PSA :
- patient > 69 years old, not necessary
- patient < 69 years old, PSA<20 and if 4<PSA<20, the ratio free PSA/total PSA must be >10%
- patient with renal clearance >60 estimated with MDRD
- patient affiliated to the social security
Exclusion Criteria:
- personal or familial history of prostatic or genito-urinary cancer
- personal history of pelvic irradiation
- personal history of hormone-therapy
- personal history of prostatic adenomectomy by abdominal approach
- personal history of allergy to beta-lactamines
- urinary tract infection or bacterial colonisation at the time of procedure
- carbapenems treatment in the two weeks before surgery
- hyperresponsivness to ertapenem or other carbapenems antibiotic
- patient with renal clearance estimated with MDRD <60
- patient with catheter or probe permanently
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: group A
One single perfusion of 1g of ertapenem 1 hour prior to prostate surgical resection
|
One single injection of 1g of ertapenem before surgery
|
Eksperimentel: group B
One single perfusion of 1g of ertapenem 12 hour prior to prostate surgical resection
|
One single injection of 1g of ertapenem before surgery
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Prostatic concentration of ertapenem
Tidsramme: at the time of surgery
|
To observe whether a significant intra-prostatic concentration of ertapenem can be obtained after a pre-operative single administration.
|
at the time of surgery
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Prostatic concentration of ertapenem
Tidsramme: at the time of surgery
|
To observe the difusion of ertapenem by comparing 1h versus12h injection prior to surgery
|
at the time of surgery
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Studiestol: Olivier Lortholary, Md, PhD, Service de Maladies Infectieuses et Tropicales, Hôpital Necker, 149 rue de Sèvres
- Ledende efterforsker: Marc-Olivier Timsit, Md, PhD, Service d'Urologie, HEGP, 20 rue Leblanc, 75015 Paris, France.
Publikationer og nyttige links
Generelle publikationer
- Tomera KM, Burdmann EA, Reyna OG, Jiang Q, Wimmer WM, Woods GL, Gesser RM; Protocol 014 Study Group. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002 Sep;46(9):2895-900. doi: 10.1128/AAC.46.9.2895-2900.2002.
- Alhambra A, Cuadros JA, Cacho J, Gomez-Garces JL, Alos JI. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother. 2004 Jun;53(6):1090-4. doi: 10.1093/jac/dkh218. Epub 2004 Apr 29.
- Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods GL, Gesser RM; Protocol 021 Study Group. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology. 2002 Jul;60(1):16-22. doi: 10.1016/s0090-4295(02)01664-3.
- Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii67-74. doi: 10.1093/jac/dkh208.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- P090205
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Ertapenem
-
University Medical Center GroningenAfsluttet
-
University of MichiganAfsluttet
-
Catholic University of the Sacred HeartMerck Sharp & Dohme LLCUkendtAllergi | IgE-medieret overfølsomhedItalien
-
Klinikum Hanover-Siloah HospitalUkendtAkut sygdom | Divertikulit, tyktarmTyskland
-
Merck Sharp & Dohme LLCAfsluttet
-
Prince of Songkla UniversityUkendtPatienter med Urosepis og modtog Ertapenem til behandlingThailand
-
Merck Sharp & Dohme LLCAfsluttet
-
Merck Sharp & Dohme LLCAfsluttetLungebetændelse | Urinvejsinfektion | Infektion
-
Albany College of Pharmacy and Health SciencesMerck Sharp & Dohme LLCAfsluttetSlutstadie nyresygdom | Kontinuerlig ambulatorisk peritonealdialyseForenede Stater